Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Dec. 26, 2024	Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture [Webcast]	Corporate
Dec. 24, 2024	Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia（PDF/152KB）	Products
Dec. 18, 2024	Sumitomo Pharma Announces Personnel Change	Corporate
Dec. 17, 2024	Sumitomo Pharma Presentation for the Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture（PDF/552KB）	Corporate
Dec. 17, 2024	Sumitomo Chemical Presentation for the Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture（PDF/671KB）	Corporate
Dec. 17, 2024	Sumitomo Chemical and Sumitomo Pharma to Establish Regenerative Medicine and Cell Therapy Joint Venture	Corporate

Jan. 31, 2025	Third Quarter of FY2024 financial results announcement (planned, 3:30 p.m.)